Is BPC-157 Legal in South Carolina?

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. Researchers have studied it primarily in rodent models for tendon healing, gut repair, and neurological recovery. No Phase III human clinical trial has yet brought it to FDA approval. That gap between promising preclinical data and approved human use is exactly where legal complexity lives.

The Compound's Research Background

Animal studies, including work published in the Journal of Physiology and Pharmacology, have shown BPC-157 may accelerate tendon-to-bone healing and reduce inflammation in rat models [1]. A 2021 review in Biomedicines catalogued dozens of rodent studies across gastrointestinal, musculoskeletal, and neurological injury models [2]. None of these translate automatically into legal human use in any U.S. State, South Carolina included.

Why State Law Alone Cannot Answer This Question

South Carolina has not passed legislation that specifically names BPC-157. The state's Pharmacy Practice Act (Title 40, Chapter 43, South Carolina Code of Laws) governs compounding and dispensing but defers to federal standards on which bulk drug substances may legally enter a compounded preparation [3]. Because federal law sets the ceiling, understanding FDA's position is the only way to understand what is currently permissible in Charleston, Columbia, or Greenville.

Federal FDA Framework: The Bulks List and Compounding Law

The FDA's authority over compounded drugs flows from Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013 [4]. These sections determine which bulk drug substances a pharmacy may use when compounding a preparation that has no commercially available FDA-approved equivalent.

How the Bulks List Works

For a bulk substance to be lawfully used in a 503A compounded preparation, it must appear on the FDA's "Category 1" positive list, or it must be the subject of an ongoing evaluation that has not resulted in a negative determination. The FDA publishes and updates this list through the Federal Register [5]. BPC-157 was nominated for evaluation and, as of the FDA's 2023 and 2024 guidance communications, it has not been placed on the positive list. The agency has signaled concerns about insufficient safety and efficacy data for human use.

503A vs. 503B: Different Rules, Same Core Problem

A 503A pharmacy compounds for an individual patient based on a valid prescription from a licensed practitioner. A 503B outsourcing facility compounds in larger quantities for healthcare providers, without patient-specific prescriptions, and faces stricter FDA oversight including Current Good Manufacturing Practice (CGMP) standards [6]. Under both pathways, using a bulk substance that the FDA has declined to include on the positive list exposes the pharmacy to enforcement action. That is the operative risk for BPC-157 as of mid-2025.

The FDA's 2023 Enforcement Signals

The FDA issued warning letters to multiple peptide compounding pharmacies between 2022 and 2024, citing bulk substances not on the approved list [7]. BPC-157 appeared by name in agency communications referencing substances under active review. The FDA's position has not risen to a formal final rule banning it outright, but the agency's enforcement discretion has tightened considerably. Clinicians and pharmacies operating in this space should consult the FDA's current bulks list status before initiating any new patient on compounded BPC-157 [8].

South Carolina State Law: What the Board of Pharmacy Actually Says

South Carolina's Board of Pharmacy operates under S.C. Code Ann. Section 40-43-10 et seq. And adopts by reference USP standards and, critically, federal compounding law [3]. The Board does not maintain a separate state-level peptide approval list. This means that if FDA enforcement classifies BPC-157 as an impermissible bulk substance, a South Carolina-licensed pharmacy that compounds it risks disciplinary action from the Board of Pharmacy, independent of any state criminal statute.

The Medical Practice Act and Prescriber Liability

South Carolina's Medical Practice Act (S.C. Code Ann. Section 40-47-5 et seq.) requires physicians to practice within the standard of care [9]. Prescribing a compounded preparation containing a bulk substance that the FDA has not authorized does not automatically violate the Medical Practice Act, but it does place the prescriber in a difficult medico-legal position if a patient is harmed. The South Carolina Medical Board has not issued a formal opinion on BPC-157 as of this writing.

No State Scheduling of BPC-157

South Carolina's Controlled Substances Act schedules drugs under Title 44, Chapter 53. BPC-157 does not appear in any schedule [10]. It is not a controlled substance in South Carolina. The absence of scheduling does not mean it is freely legal to sell or administer; it simply means criminal penalties tied to controlled-substance statutes do not apply.

The HealthRX Legal-Access Framework for unscheduled, unapproved peptides in South Carolina can be summarized as a three-gate test. Gate 1: Is the bulk substance on the FDA 503A/503B positive list or in active non-negative evaluation? Gate 2: Does a licensed South Carolina practitioner find a legitimate clinical rationale and document it? Gate 3: Is a 503A- or 503B-compliant pharmacy willing to compound the preparation given current FDA guidance? All three gates must be open simultaneously for a prescription to be considered legally defensible in the current regulatory environment.

How to Get BPC-157 in South Carolina: Legal Pathways

There is no over-the-counter or direct-consumer route to legally obtain injectable BPC-157 in South Carolina for human use. Every pathway that avoids criminal or regulatory exposure runs through a licensed clinician and a compounding pharmacy.

Pathway 1: Licensed Clinician Prescription via a 503A Pharmacy

A physician, nurse practitioner, or physician assistant licensed in South Carolina may, after a clinical evaluation, write a prescription for a compounded BPC-157 preparation if they believe a clinical rationale exists and if the pharmacy they select is willing to compound it. The patient and prescriber share the regulatory risk that attaches to current FDA bulks list uncertainty. Patients should ask any prescriber to confirm that the pharmacy they use operates under current 503A standards and that the pharmacy has reviewed FDA guidance on BPC-157 specifically [4].

Pathway 2: Participation in a Clinical Trial

ClinicalTrials.gov lists ongoing and recruiting studies involving peptide therapies. If a South Carolina academic medical center or research hospital were to sponsor or participate in a BPC-157 trial under an Investigational New Drug (IND) application, patients enrolled in that trial could receive the compound legally [11]. As of mid-2025, no active Phase II or Phase III trial for BPC-157 in human subjects is listed as recruiting in South Carolina on ClinicalTrials.gov.

Pathway 3: Research Use (Not for Human Administration)

BPC-157 is available from chemical suppliers as a research reagent for in-vitro laboratory use. Federal law does not prohibit purchasing it for legitimate laboratory research. Purchasing it in this context and then self-administering it is a separate act that falls outside legal protection and carries substantial health risk given the absence of pharmaceutical-grade quality assurance [12].

What Is Not a Legal Pathway

Ordering BPC-157 injectable vials from offshore websites, gray-market peptide suppliers, or fitness vendors is not a legal pathway for human use. The FDA has authority under 21 U.S.C. Section 331 to prohibit introduction of adulterated or misbranded drugs into interstate commerce [13]. Imported peptides lacking FDA oversight may contain microbial contamination, incorrect concentrations, or undisclosed adulterants. A 2018 analysis published in JAMA Internal Medicine found that a substantial fraction of products sold as peptides or research chemicals did not match their labeled composition [14].

Risks of Accessing BPC-157 Outside Legal Channels

The risks divide into two categories: legal and medical. On the legal side, knowingly importing or distributing an unapproved drug intended for human use violates the Federal Food, Drug, and Cosmetic Act. Penalties may include seizure of the product, injunctions, and in cases of commercial distribution, criminal prosecution [13]. On the medical side, self-injecting a peptide of uncertain purity raises the risk of infection, abscess, systemic sepsis, and anaphylaxis.

What the Preclinical Data Does and Does Not Show

A 2019 paper in Current Neuropharmacology reported that BPC-157 reduced dopamine system dysfunction in rat models of Parkinson's-like injury [15]. A rodent study in the European Journal of Pharmacology found accelerated Achilles tendon healing with BPC-157 injection compared with saline controls [16]. These results are compelling enough to justify continued research. They are not, by themselves, a safety and efficacy profile sufficient for FDA approval, which requires demonstration of safety and efficacy in adequate and well-controlled human trials under 21 C.F.R. Section 314.126 [17].

Absence of Long-Term Human Safety Data

No published randomized controlled trial has evaluated BPC-157's long-term safety profile in humans at therapeutic doses. The FDA's requirement for this data before approving a drug is not bureaucratic formality. Gastrointestinal peptide analogs can have effects on angiogenesis and tumor microenvironments that may not manifest in short rodent studies [18]. A licensed clinician prescribing compounded BPC-157 today is making a risk-benefit decision with an incomplete human safety dataset.

What South Carolina Patients Should Ask a Prescriber

A patient who is genuinely interested in BPC-157 therapy should come to a clinical consultation prepared. The following questions help assess whether a prescribing clinician is operating thoughtfully within the current legal and clinical field.

Key Questions for Your Appointment

Ask the clinician to explain the current FDA bulks list status of BPC-157 and how that affects the prescription they are writing. Ask which specific 503A-accredited pharmacy will fill the prescription, and whether that pharmacy has confirmed willingness to compound BPC-157 given current agency guidance. Ask what clinical outcome measures will be tracked, and what the plan is if the FDA issues a final negative determination on BPC-157's bulks list status.

A prescriber who cannot answer these questions clearly may not be operating with adequate regulatory awareness. The American Association of Clinical Endocrinology guidelines on off-label and compounded therapies advise that practitioners document the rationale for any compounded preparation in the medical record [19].

"Physicians who prescribe compounded drugs should be aware that such products lack FDA approval of safety and effectiveness and should use them only when an FDA-approved drug does not meet the clinical need of an individual patient," states the FDA's own guidance document on compounding for practitioners [20].

Telehealth Access in South Carolina

South Carolina permits telehealth prescribing under the South Carolina Telehealth Alliance framework and state law. A licensed South Carolina practitioner conducting a telehealth visit may write a prescription for a compounded peptide if state and federal requirements are met [9]. Several HealthRX-affiliated clinicians are licensed in South Carolina and can conduct evaluations for patients interested in peptide therapy. Any prescription would go to a compounding pharmacy reviewed for current 503A compliance.

Current FDA Regulatory Trajectory for BPC-157

The FDA's regulatory posture toward unapproved peptides has tightened steadily since 2020. The agency removed several peptides from the 503A bulks list in 2022 and 2023, including BPC-157 in certain formulations, citing the lack of clinical evidence [7]. This does not amount to a permanent, finalized prohibition but it does represent a direction of travel that clinicians and patients need to monitor actively.

What a Final Negative Determination Would Mean

If the FDA places BPC-157 on the "Category 2" negative list, 503A pharmacies would be prohibited from using it as a bulk substance nationwide [5]. That determination would close the compounding pathway in South Carolina without any additional state legislative action required, because South Carolina's pharmacy law incorporates federal standards by reference [3].

Monitoring the FDA Docket

The FDA maintains a public docket for the 503A bulks evaluation process at regulations.gov and publishes updates in the Federal Register. Patients and practitioners in South Carolina can follow docket number FDA-2015-N-3469 for 503A bulks list updates, which includes BPC-157's evaluation status [5].